Arcline Investment Management, a Nashville, Tennessee-based private equity firm, announced that it has entered into a definitive agreement to sell its portfolio company Resolution Medical to Resonetics.
Based in Fridley, Minnesota, Resolution Medical is a scaled, end-to-end engineering services and outsourced manufacturing partner focused on complex Class II and III devices for medical technology markets including structural heart, cardiology and vascular, electrophysiology and neuromodulation therapies. With 240 employees, Resolution Medical provides expertise in device design, prototyping, bio-simulation and product design, through to finished device manufacturing.
Founded in 1987, Resonetics is a pioneer in advanced engineering, product development, prototyping and manufacturing solutions for the life sciences industry. Resonetics is backed by leading private equity firms Carlyle and GTCR.
Piper Sandler & Co. served as financial advisor, and Bass, Berry & Sims PLC and Fredrikson & Byron P.A. served as legal advisors to Resolution Medical in connection with the transaction.
The acquisition is expected to close in the first quarter of 2026, subject to regulatory approvals and customary closing conditions. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 17th Life Sciences R&D acquisition of the year, as well as the eighth in the contract development and manufacturing organization (CDMO) subsector. Other acquires in the space this year include Gilde Healthcare, Arterex, Agno Pharma, 1315 Capital, Artis BioSolutions, Tri-Imaging Solutions and Siegfried Holding. There were 83 Life Sciences R&D deals announced in 2025, including 42 CDMO deals. In 2024, there were 92 Life Sciences R&D and 30 CDMO transactions announced.
